Market cap of Clarus Therapeutics Holdings Inc. [CRXT] reaches 18.28M – now what?


Clarus Therapeutics Holdings Inc. [NASDAQ: CRXT] loss -15.47% or -0.11 points to close at $0.63 with a heavy trading volume of 12195207 shares. The company report on April 28, 2022 that Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate).

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions.

Upon issuance, this patent will be listed in FDA’s Orange Book, bringing the total number of Orange Book-listed patents covering JATENZO to eight.

It opened the trading session at $0.6788, the shares rose to $0.70 and dropped to $0.6146, the range by which the price of stock traded the whole day. The daily chart for CRXT points out that the company has recorded -85.04% loss over the past six months. However, it is still -3.28% lower than its most recent low trading price.

If we look at the average trading volume of 10.50M shares, CRXT reached to a volume of 12195207 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Clarus Therapeutics Holdings Inc. [CRXT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRXT shares is $7.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRXT stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Clarus Therapeutics Holdings Inc. is set at 0.42, with the Price to Sales ratio for CRXT stock in the period of the last 12 months amounting to 1.31.

Trading performance analysis for CRXT stock

Clarus Therapeutics Holdings Inc. [CRXT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -65.25. With this latest performance, CRXT shares dropped by -69.93% in over the last four-week period, additionally sinking by -85.04% over the last 6 months – not to mention a drop of -93.78% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRXT stock in for the last two-week period is set at 39.82, with the RSI for the last a single of trading hit 36.01, and the three-weeks RSI is set at 41.64 for Clarus Therapeutics Holdings Inc. [CRXT]. The present Moving Average for the last 50 days of trading for this stock 1.1069, while it was recorded at 0.7695 for the last single week of trading, and 4.2994 for the last 200 days.

Clarus Therapeutics Holdings Inc. [CRXT]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Clarus Therapeutics Holdings Inc. [CRXT] shares currently have an operating margin of -284.67 and a Gross Margin at +80.51. Clarus Therapeutics Holdings Inc.’s Net Margin is presently recorded at -291.02.

Return on Equity for this stock declined to -332.62, with Return on Assets sitting at -73.06.

Clarus Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.80.

An analysis of insider ownership at Clarus Therapeutics Holdings Inc. [CRXT]

There are presently around $3 million, or 78.20% of CRXT stock, in the hands of institutional investors. The top three institutional holders of CRXT stocks are: BRACEBRIDGE CAPITAL, LLC with ownership of 2,002,495, which is approximately 0% of the company’s market cap and around 1.10% of the total institutional ownership; ARMISTICE CAPITAL, LLC, holding 1,929,876 shares of the stock with an approximate value of $1.21 million in CRXT stocks shares; and VANGUARD GROUP INC, currently with $0.1 million in CRXT stock with ownership of nearly New of the company’s market capitalization.

Positions in Clarus Therapeutics Holdings Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 9 institutional holders increased their position in Clarus Therapeutics Holdings Inc. [NASDAQ:CRXT] by around 2,176,025 shares. Additionally, 8 investors decreased positions by around 133,815 shares, while 2 investors held positions by with 1,993,257 shares. The mentioned changes placed institutional holdings at 4,303,097 shares, according to the latest SEC report filing. CRXT stock had 7 new institutional investments in for a total of 2,148,048 shares, while 7 institutional investors sold positions of 103,393 shares during the same period.